SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
NEW YORK, March 14, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased SCYNEXIS, Inc. (NASDAQ:SCYX) securities (1) pursuant and/or traceable to the Registration Statement and Prospectus issued in connection with the Company’s Initial Public Offering on or about May 2, 2014 and/or (2) between May 2, 2014 and March 2, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra/scynexis-inc. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (i) SCYNEXIS’s lead product SCY-078 posed substantial undisclosed health and safety risks; (ii) consequently, the Company had overstated the drug’s approval prospects and/or commercial viability; and (iii) as a result of the foregoing, SCYNEXIS’s public statements were materially false and misleading at all relevant times.
On March 2, 2017, SCYNEXIS announced that the U.S. Food and Drug Administration “informed the Company to hold the initiation of any new clinical studies with the intravenous (IV) formulation of SCY-078 until the FDA completes a review of all available pre-clinical and clinical data” of the formulation. The hold stems from “three mild-to-moderate thrombotic events in healthy volunteers” receiving the formulation.
If you suffered a loss in SCYNEXIS you have until May 8, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/scynexis-inc.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
